Great Point Partners Has Increased Biocryst Pharmaceuticals Cmn (BCRX) Stake; As Paycom Software (PAYC) Market Valuation Rose, Shareholder Fcm Investments Decreased Stake

May 18, 2018 - By Linda Rogers

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Logo

Jeffrey Jay increased its stake in Biocryst Pharmaceuticals Inc Cmn (BCRX) by 190.22% based on its latest 2017Q4 regulatory filing with the SEC. Great Point Partners Llc bought 3.11M shares as the company’s stock declined 0.98% with the market. The hedge fund run by Jeffrey Jay held 4.75 million shares of the health care company at the end of 2017Q4, valued at $23.33M, up from 1.64M at the end of the previous reported quarter. Great Point Partners Llc who had been investing in Biocryst Pharmaceuticals Inc Cmn for a number of months, seems to be bullish on the $572.56M market cap company. The stock decreased 1.69% or $0.1 during the last trading session, reaching $5.8. About 178,187 shares traded. BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) has declined 43.31% since May 18, 2017 and is downtrending. It has underperformed by 54.86% the S&P500.

Fcm Investments decreased its stake in Paycom Software Inc. (PAYC) by 10.24% based on its latest 2017Q4 regulatory filing with the SEC. Fcm Investments sold 5,230 shares as the company’s stock rose 33.33% while stock markets declined. The hedge fund held 45,851 shares of the technology company at the end of 2017Q4, valued at $3.68 million, down from 51,081 at the end of the previous reported quarter. Fcm Investments who had been investing in Paycom Software Inc. for a number of months, seems to be less bullish one the $6.10B market cap company. The stock increased 1.48% or $1.5 during the last trading session, reaching $103.19. About 141,277 shares traded. Paycom Software, Inc. (NYSE:PAYC) has risen 92.63% since May 18, 2017 and is uptrending. It has outperformed by 81.08% the S&P500.

More news for Paycom Software, Inc. (NYSE:PAYC) were recently published by: Globenewswire.com, which released: “Recent Analysis Shows Paycom Software, American Renal Associates, Knowles, Timken, Nevro, and Unisys Market …” on May 15, 2018. Fool.com‘s article titled: “Paycom Software Starts 2018 Strong, Increases Guidance” and published on May 02, 2018 is yet another important article.

Analysts await Paycom Software, Inc. (NYSE:PAYC) to report earnings on August, 7. They expect $0.36 EPS, up 50.00% or $0.12 from last year’s $0.24 per share. PAYC’s profit will be $21.26 million for 71.66 P/E if the $0.36 EPS becomes a reality. After $0.69 actual EPS reported by Paycom Software, Inc. for the previous quarter, Wall Street now forecasts -47.83% negative EPS growth.

Fcm Investments, which manages about $373.26M and $70.14M US Long portfolio, upped its stake in Intuitive Surgical Inc (NASDAQ:ISRG) by 9,021 shares to 14,430 shares, valued at $5.27M in 2017Q4, according to the filing.

Among 19 analysts covering Paycom Software (NYSE:PAYC), 11 have Buy rating, 0 Sell and 8 Hold. Therefore 58% are positive. Paycom Software had 71 analyst reports since August 5, 2015 according to SRatingsIntel. The stock of Paycom Software, Inc. (NYSE:PAYC) has “Hold” rating given on Wednesday, May 2 by First Analysis. The rating was maintained by Northland Capital on Thursday, January 11 with “Buy”. The rating was maintained by Wells Fargo with “Buy” on Wednesday, November 1. Oppenheimer maintained the stock with “Buy” rating in Wednesday, August 2 report. UBS initiated the stock with “Buy” rating in Tuesday, April 19 report. The firm has “Buy” rating given on Monday, June 26 by Canaccord Genuity. The firm has “Equal Weight” rating by Barclays Capital given on Wednesday, August 5. On Wednesday, July 19 the stock rating was maintained by RBC Capital Markets with “Hold”. Credit Suisse maintained it with “Neutral” rating and $95 target in Wednesday, May 2 report. The firm has “Neutral” rating given on Monday, July 10 by Mizuho.

Investors sentiment decreased to 1.61 in 2017 Q4. Its down 0.08, from 1.69 in 2017Q3. It dived, as 16 investors sold BCRX shares while 20 reduced holdings. 22 funds opened positions while 36 raised stakes. 87.26 million shares or 9.34% more from 79.80 million shares in 2017Q3 were reported. D E Shaw Incorporated holds 939,473 shares or 0.01% of its portfolio. Arrowmark Colorado Hldgs Ltd Liability Com holds 12,019 shares or 0% of its portfolio. Zurcher Kantonalbank (Zurich Cantonalbank) reported 0% in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX). Connor Clark & Lunn Investment Mngmt Ltd invested 0% of its portfolio in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX). Fincl Bank Of Montreal Can invested 0% of its portfolio in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX). 30,600 were accumulated by Oberweis Asset Inc. Janney Montgomery Scott Ltd Limited Liability Company has 30,735 shares for 0% of their portfolio. California State Teachers Retirement Systems holds 154,455 shares or 0% of its portfolio. Nebraska-based Ameritas Investment has invested 0% in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX). Emory University has 383,768 shares for 1.62% of their portfolio. Pillar Pacific Capital Management Limited Co reported 11,650 shares. Ra Capital stated it has 6.98M shares. Amalgamated Natl Bank holds 13,360 shares. Jpmorgan Chase holds 0% or 21,138 shares in its portfolio. Legal And General Group Public Limited invested 0% of its portfolio in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX).

Great Point Partners Llc, which manages about $935.83 million and $586.07 million US Long portfolio, decreased its stake in Global Blood Therapeutics Inc. Cmn (Call) by 360,498 shares to 200,000 shares, valued at $7.87 million in 2017Q4, according to the filing. It also reduced its holding in Concert Pharmaceuticals Inc Cmn (NASDAQ:CNCE) by 1.34 million shares in the quarter, leaving it with 669,472 shares, and cut its stake in Myovant Sciences Ltd Cmn.

Among 14 analysts covering BioCryst Pharmaceuticals (NASDAQ:BCRX), 12 have Buy rating, 0 Sell and 2 Hold. Therefore 86% are positive. BioCryst Pharmaceuticals had 35 analyst reports since August 7, 2015 according to SRatingsIntel. The firm earned “Buy” rating on Tuesday, February 9 by Rodman & Renshaw. Jefferies upgraded the stock to “Buy” rating in Wednesday, September 6 report. The firm has “Outperform” rating given on Tuesday, January 2 by RBC Capital Markets. RBC Capital Markets maintained BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) on Thursday, November 2 with “Hold” rating. Jefferies maintained BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) on Friday, August 5 with “Hold” rating. H.C. Wainwright maintained it with “Buy” rating and $10.0 target in Tuesday, January 23 report. Jefferies downgraded it to “Buy” rating and $2 target in Tuesday, February 9 report. The company was upgraded on Wednesday, September 6 by JP Morgan. As per Friday, December 16, the company rating was upgraded by JMP Securities. H.C. Wainwright maintained the shares of BCRX in report on Tuesday, August 8 with “Buy” rating.

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Ratings Chart

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


>